Patients with HER2-enriched breast cancer had a 10-year survival rate of 92.44% (95% CI, 73.02–98.06) for BCT and 66.23% (95% CI, 49.73–78.43) for mastectomy. The gene discussed is ERBB2; the disease is breast carcinoma.